STAT+: Pharmalittle: Genentech weighs delaying cancer therapy after drug pricing law; Novo continues to restrict supplies of low-dose Wegovy

CEO says Medicare negotiation could encourage Genentech to slow-walk ovarian cancer drug for smaller population.
Click here to view original post


ADVERTISEMENT — Advertise With Biotech Networks